Cognition Therapeutics (CGTX) Non-Current Assets (2020 - 2026)
Cognition Therapeutics (CGTX) reported Non-Current Assets of $326000.0 for Q1 2026, down 48.58% year-over-year from $634000.0 in Q1 2025, and down 18.3% on a QoQ basis from $399000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Non-Current Assets data on file, last reported at $326000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 48.58% year-over-year to $326000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 37.17% YoY) and the FY2025 annual result came in at $399000.0, down 41.24% from the prior year.
- Non-Current Assets fell to $326000.0 in Q1 2026 per CGTX's latest filing, from $399000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.9 million in Q1 2023 and bottomed at $326000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $883000.0 (2024), against an average of $1.4 million.
- The widest annual swing landed in 2022, when Non-Current Assets surged 1815.86%; it then sank 72.58% in 2024.
- Tracing CGTX's Non-Current Assets over 5 years: stood at $2.8 million in 2022, then tumbled by 66.13% to $941000.0 in 2023, then declined by 27.84% to $679000.0 in 2024, then tumbled by 41.24% to $399000.0 in 2025, then decreased by 18.3% to $326000.0 in 2026.
- Per Business Quant, the three latest CGTX Non-Current Assets figures stand at $326000.0 (Q1 2026), $399000.0 (Q4 2025), and $512000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 22.66 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | 326,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 326,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 512,000.00 |
| Jun 30, 2025 | 573,000.00 |
| Mar 31, 2025 | 634,000.00 |
| Dec 31, 2024 | 679,000.00 |
| Sep 30, 2024 | 749,000.00 |
| Jun 30, 2024 | 819,000.00 |
| Mar 31, 2024 | 883,000.00 |
| Dec 31, 2023 | 941,000.00 |
| Sep 30, 2023 | 2.73 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | 2.86 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.63 Mn |
| Jun 30, 2022 | 2.07 Mn |
| Mar 31, 2022 | 2.26 Mn |
| Dec 31, 2021 | 145,000.00 |
| Sep 30, 2021 | 3.35 Mn |
| Dec 31, 2020 | 211,000.00 |